Genmab signs antibody research deal with Janssen Biotech
COPENHAGEN (Reuters) - Danish biopharma firm Genmab has agreed to collaborate with Janssen Biotech to create and develop antibodies using its DuoBody technology platform and will receive an upfront payment of $3.5 million, Genmab said.
Under the terms of the deal, Janssen will fully fund the research to be done at Genmab, and Genmab will potentially be entitled to milestone and license payments of up to about $175 million for each product as well as royalties on any commercialized products, Genmab said late on Thursday.
The deal with Janssen followed a collaboration agreement with Novartis in June to use Genmab's DuoBody technology.
The DuoBody platform, introduced in 2010 is a technology for the discovery and development of antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease, Genmab said in the statement.
(Reporting by John Acher; Editing by Eric Meijer)
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- Yemeni al Qaeda says attack on hospital was mistake
- Insight: For Chinese farmers, a rare welcome in Russia's Far East